Latecomer Brigatinib Looking Good In First-Line NSCLC Head-To-head

27 Jul 2018

Takeda's ALK inhibitor meets primary endpoint in interim analysis from critical first-line lung cancer head-to-head study, helping validate Ariad acquisition, but will be a relative class latecomer to the setting.

Cancer cells on scientific background.3d illustration — PROMISING RESULTS FOR BRIGATINIB IN FIRST-LINE NSCLC • Source: Shutterstock

Latecomer Brigatinib Looking Good In First-Line NSCLC Head-To-head

More from Anticancer

More from Therapy Areas